Scientists Uncover Gut Microbiota's Role in Coronary Artery Disease
The global burden of cardiovascular diseases is staggering, claiming the lives of nearly 20 million people annually. While genetic and environmental factors significantly influence disease risk and severity, the role of microbes, particularly in coronary artery disease (CAD), has been a subject of growing interest. Recent studies suggest that gut microbiota contributes to CAD progression through various mechanisms, but the specific bacterial contributions have remained largely unknown.
However, a groundbreaking study published in mSystems by researchers in Seoul has shed new light on this complex relationship. Led by Han-Na Kim, Ph.D., a genomicist at the Samsung Advanced Institute for Health Sciences and Technology at Sungkyunkwan University, the research team delved into the gut microbes and their impact on CAD. By employing metagenomic sequencing, they compared fecal samples from 14 individuals with CAD to those from 28 healthy individuals.
The findings were remarkable. Kim and her colleagues identified 15 bacterial species associated with CAD, revealing a shift in gut microbiota function. They observed a dramatic increase in inflammation and metabolic imbalance, including a decline in the presence of protective short-chain fatty acid producers, such as Faecalibacterium prausnitzii. Additionally, certain pathways, like the urea cycle, were overactivated, correlating with disease severity.
One of the most intriguing discoveries was the potential for beneficial bacteria to exhibit harmful effects. Kim explained that microbes typically considered friendly, such as Akkermansia muciniphila and F. prausnitzii, can display different functions depending on their origin. Those from healthy individuals may behave differently than those from diseased guts.
The study also highlighted the complexity of gut microbiota's role in CAD. For instance, previous research found reduced levels of Lachnospiraceae species associated with CAD, but the new study revealed higher levels of other Lachnospiraceae types. Kim humorously likened Lachnospiraceae to Dr. Jekyll and Mr. Hyde, emphasizing the variability in its species' behavior. Some species are depleted in individuals with CAD, while others surge, leaving the question of which strains are beneficial and which are detrimental.
Looking ahead, Kim's team aims to integrate microbial data with genetic and metabolomic information to create a more precise understanding of CAD's causal pathways. Their ultimate goal is to develop precision-based interventions, translating microbial insights into effective tools and strategies for preventing cardiovascular disease.
Prevention, according to Kim, holds the most promise for reducing the global heart disease burden. Microbial therapies could revolutionize screening methods, such as stool-based assessments, and nutritional interventions that promote beneficial bacteria or inhibit harmful pathways. This research opens up exciting possibilities for a more comprehensive approach to cardiovascular disease management.
